TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02640781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-expandable metal stent insertion(covered stent)
Description: Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
Study: NCT04388839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV push over 6-10 minutes with dosing ranging from 4mg-25mg
Study: NCT02205606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 5/10mg
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 10/10mg
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 20/10mg
Description: P.O.
Study: NCT03180359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recommended vaccine scheme according to French Vaccine Schedule 2015
Description: * BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children
Study: NCT01626911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion of low molecular weight heparin in celiac trunk
Description: Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General treatment
Description: Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: General treatment
Description: Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
Study: NCT01123577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitor Group
Description: Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
Study: NCT03535545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
Study: NCT04388839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin D
Description: Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
Study: NCT02594397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoints combination 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupoints combination 2

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupoints combination
Study: NCT02172079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real mobilization-with-movement (MWM)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilization-with-movement (MWM)
Study: NCT00979446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided
Description: Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed
Description: Received study materials but no phone coaching
Study: NCT02575573

Intervention type: OTHER
Intervention: Factors influencing resuscitation decisions of patients

Intervention type: OTHER
Intervention: Factors leading to not asking patients about resuscitation preference
Study: NCT00832546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04388839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
Study: NCT00832546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NGX426 (Powder in solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NGX426 (Powder in solution)
Study: NCT02529241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg
Study: NCT02640781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: self-expandable metal stent insertion(uncovered stent)
Description: Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
Study: NCT03737097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Spaced Education
Description: Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure Education
Description: The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
Study: NCT02027558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia treatment & PAP adherence
Description: Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General sleep education
Description: Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
Study: NCT04783454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
Study: NCT04676984

Intervention type: OTHER
Group type: OTHER
Intervention: Consultations
Description: The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
Study: NCT02529241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg
Study: NCT03627910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: symbiotic
Description: Feed supplementation
Study: NCT00114244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study: NCT03535545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
Study: NCT00114244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03535545

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
Study: NCT02886221

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverdin-Isham Osteotomy
Description: Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
Study: NCT00203372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 and TAC
Description: Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Description: placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 and TAC
Description: one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 15 and TAC
Description: one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
Study: NCT03603184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
Study: NCT02695719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study: NCT03603184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
Study: NCT04388839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Pill
Description: Based on Body Surface Area (BSA) round to nearest 25mg
Study: NCT01939808

Intervention type: OTHER
Group type: OTHER
Intervention: Splint Neutral

Intervention type: OTHER
Group type: OTHER
Intervention: Splint Extended
Study: NCT03655626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis Watch
Description: The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
Study: NCT02695719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules
Study: NCT03627910

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc and arginine
Description: Feed supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc and arginine
Description: Feed supplementation
Study: NCT04351841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinogalactan
Description: A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
Study: NCT00722631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
Study: NCT02971982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab /Dexamethasone/cyclophosphamide
Description: rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade/Dexamethasone/cyclophosphamide
Description: Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
Study: NCT02212522

Intervention type: OTHER
Intervention: Collect of environmental data on T1D patients before diagnosis
Description: Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data

Intervention type: GENETIC
Intervention: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
Description: Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)

Intervention type: OTHER
Intervention: Collect of clinical data on the disease and its evolution
Description: Collect of clinical data on the disease and its evolution every 6 months after enrollment

Intervention type: OTHER
Intervention: Collect of environmental data on French controls (age-matched for T1D patients)
Description: Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data

Intervention type: GENETIC
Intervention: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
Description: Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
Study: NCT00947817

Intervention type: OTHER
Group type: OTHER
Intervention: ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test
Study: NCT01793441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in different stages of the study for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7314
Description: RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
Study: NCT00738699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MORAb-003 (farletuzumab)
Description: Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Study: NCT00589849

Intervention type: PROCEDURE
Intervention: T-wave Alternans
Description: T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
Study: NCT04035798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine or placebo
Description: BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine or placebo
Description: BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
Study: NCT04993261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo dual energy CT scan
Study: NCT02887833

Intervention type: OTHER
Intervention: Clinical biomarker (thermal sensory testing)
Description: Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
Study: NCT01899261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SBRT
Study: NCT00084383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination.
Study: NCT03893370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RejuvenAir System
Description: RejuvenAir Metered CryoSpray

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control Procedure
Description: Sham Control Procedure
Study: NCT03816384

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care urinary drainage system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLC Group
Description: Urinary drainage system with active drain line clearance and plain silicone catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLCS Group
Description: Urinary drainage system with active drain line clearance and silver-doped silicone catheter.